B

BETA DRUGS LIMITED

BETA
Market snapshot · 2026-08-11 00:18 UTC

2,504.00

+₹130.30 (+5.49%)

MARKET CAP

₹2.53K Cr

STOCK P/E

56.7x

52W HIGH

₹2,674.00

52W LOW

₹990.10

BOOK VALUE

₹241.55

EPS

₹44.15

ROE

SECTOR

Health Care

DEBT/EQUITY

60.39

VOLUME

65,018

P/B RATIO

10.37x

PEG RATIO

Sector

Health Care

Themes

PharmaceuticalsAshish Kacholia PortfolioTop 20 Investors in India Portfolio
₹2,373.70₹2,043.17₹1,712.65₹1,382.13₹1,051.60VolumeAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Forecast

Analyst targets, estimate history, and probabilistic forward ranges for BETA.

Coverage check

Price Forecast

Current
₹2,504
High Target
Median Target
Low Target
Now₹2,504Aug '25Now12M Target
Price history (1Y)
Analyst target range

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange ()Probability
3M₹1,844 - ₹3,65580%
6M₹1,659 - ₹4,36680%
12M₹1,459 - ₹5,73480%
Realized vol: +53.4% · Drift: +28.7%

Revenue Forecast

₹ Cr
Jun '26Current₹56.0
Sep 2026 ETrend estimate range
High₹56.2Base₹52.0Low₹47.9
Sep '25: ₹54.0 · Dec '25: ₹50.0 · Mar '26: ₹54.0 · Jun '26: ₹56.0 · Sep '26: ₹52.0 · Dec '26: ₹48.2
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E54.050.054.056.052.048.2
PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share
Jun '26Current₹5.35
Sep 2026 ETrend estimate range
High₹2.52Base₹2.25Low₹1.98
Sep '25: ₹1.50 · Dec '25: ₹3.21 · Mar '26: ₹5.26 · Jun '26: ₹5.35 · Sep '26: ₹2.25 · Dec '26: ₹4.81
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E1.503.215.265.352.254.81
PastCurrentTrend estimate: Low / Base / High
Analyst price target unavailable from FMP/yfinance. Analyst pillar unavailable from FMP/yfinance.
Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook
Neutral
64%
Analyst Consensus
Unavailable

Analyst coverage unavailable

Mean upsideNot available

Fundamentals

Strong

Fundamentals institutional score is 73 using growth durability 72.6.

Valuation

Fairly valued

Valuation institutional score is 0 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Unavailable

No usable analyst target or recommendation data was available.

Technical Structure

Mixed Momentum

Technicals institutional score is 69 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Neutral backdrop

Recent news flow is balanced or not decisive enough to tilt the tape. Based on 8 recent ticker-linked news items.

Signal Summary

Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals StrongValuation Fairly valuedTechnical Structure Mixed MomentumMarket Sentiment Neutral backdrop

Key Data Points

Mean Target PriceUnavailable
Mean UpsideNot available
Technical Score69%
Fundamental Score73%
Data CoverageMedium

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 49.8% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +2.32). Confidence: 78%.

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/E
Strongly Overvalued

5Y Average

28.24

Current

53.76

Overvalued

41.28

Undervalued

28.91

EV/EBITDA
Strongly Overvalued

5Y Average

15.97

Current

32.08

Overvalued

21.83

Undervalued

9.86

P/S
Strongly Overvalued

5Y Average

3.07

Current

6.16

Overvalued

4.19

Undervalued

1.89

Peers & Comparison

Sector: Health Care · Theme: Pharmaceuticals

Pharmaceuticals Peers3 peers
Avg P/E: 39.3x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
AKUMS DRUGS AND PHARMA L
AKUMSPharmaceuticals
+9.6%5.9%
43.8x
Fair
+11% vs avg
+45.4%
BLUE JET HEALTHCARE LTD
BLUEJETPharmaceuticals
-17.4%26.5%
43.7x
Fair
+11% vs avg
-25.8%
JEENA SIKHO LIFECARE LTD
JSLLPharmaceuticals
+28.8%27.8%
30.3x
Undervalued
-23% vs avg
+11.6%
WHY THESE PEERS

BETA DRUGS LIMITED trades at a premium (56.7x vs peer avg 39.3x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, JEENA SIKHO LIFECARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹56 CrJun 2026

Latest net profit

₹5.93 CrJun 2026

Latest EPS

₹5.35Jun 2026

Net margin

18.2%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%5.0%10.0%15.0%20.0%0.00 Cr20 Cr40 Cr60 Cr80 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr20 Cr40 Cr60 Cr80 Cr₹0₹2₹4₹6₹8
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr15 Cr30 Cr45 Cr60 Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-115 Cr0.00 Cr115 Cr230 Cr345 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +48.2753.7466.3254.4850.2854.3555.83
Expenses +42.5548.4958.8049.7543.7444.6045.68
Operating Profit5.725.257.524.736.549.7510.15
OPM %11.85%9.77%11.34%8.68%13.01%17.94%18.18%
Other Income +-1.471.712.972.742.512.921.87
Interest1.332.812.792.973.172.871.60
Depreciation1.922.142.042.382.512.742.49
Profit before tax1.002.015.662.123.377.067.93
Tax %25.00%30.85%25.09%28.77%3.56%24.50%25.22%
Net Profit +0.751.394.231.513.255.335.93
EPS in Rs0.741.384.191.503.215.265.35
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +66.73%66.73%64.90%64.63%59.10%
FIIs +0.90%0.90%1.14%1.16%1.02%
DIIs +0.26%0.29%1.90%2.15%6.23%
Public +32.11%32.07%32.07%32.06%33.65%
Others0.01%
Jun 2026
Promoters +
FIIs +
DIIs +
Public +

Events Timeline

Investor Presentation

Jul 27, 2026PDFCompany Reports Open

Reply to Clarification- Financial results

Jul 23, 2026PDFCompany Reports Open

Clarification - Financial Results

Jul 22, 2026LinkCompany Reports Open

Copy of Newspaper Publication

Jul 21, 2026PDFCompany Reports Open

Statement of deviation(s) or variation(s) under Reg. 32

Jul 20, 2026PDFCompany Reports Open